Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
s ofthe Private Securities Litigation Reform Act of 1995 is subject to anumber of risks and uncertainties including but not limited to uncertaintyas to market acceptance of Resurgex and Resurgex Plus and the factorsidentified in the Company's 10-KSB and other documents filed with theSecurities and Exchange Commission. Actual results may differ materiallyfrom those anticipated in such forwa
Date:9/12/2007